Should all hypertensive dialysis patients receive a blocker of the renin-angiotensin system?

Research output: Contribution to journalArticle

5 Citations (Scopus)

Abstract

Cardiovascular mortality and hypertension remain common in the dialysis population, and two recent meta-analyses have suggested that antihypertensive pharmacotherapy reduces cardiovascular events in dialysis patients. Based on their benefits in other populations, blockers of the renin-angiotensin- aldosterone system (RAAS) are an attractive treatment option. The evidence that RAAS blockers improve surrogate end points is mixed. However, a recent meta-analysis found significant improvement in left ventricular mass with RAAS-blocking drugs in hemodialysis patients. Only a few trials have examined RAAS-blocking drugs and cardiovascular events in dialysis patients, and a recent meta-analysis found no significant benefit in hemodialysis patients. The single trial of peritoneal dialysis patients that reported cardiovascular events found no benefit from RAAS blockers. Fortunately, the risk of hyperkalemia appears low. Based on the available evidence, we cannot categorically recommend that all hypertensive dialysis patients be treated with RAAS blockers. We await the results of adequately powered clinical trials.

Original languageEnglish (US)
Pages (from-to)356-363
Number of pages8
JournalCurrent Hypertension Reports
Volume12
Issue number5
DOIs
StatePublished - Oct 2010
Externally publishedYes

Fingerprint

Renin-Angiotensin System
Dialysis
Meta-Analysis
Renal Dialysis
Cardiovascular Agents
Hyperkalemia
Peritoneal Dialysis
Antihypertensive Agents
Population
Biomarkers
Clinical Trials
Hypertension
Drug Therapy
Mortality
Pharmaceutical Preparations

Keywords

  • ACE inhibitor
  • ARB
  • Blood pressure
  • Cardiovascular events
  • End-stage renal disease
  • ESRD
  • Hemodialysis
  • Hypertension
  • Kidney
  • Mortality
  • Myocardial infarction
  • Peritoneal dialysis
  • RAAS
  • Renin-angiotensin system
  • Residual renal function
  • Stroke
  • Treatment

ASJC Scopus subject areas

  • Internal Medicine

Cite this

Should all hypertensive dialysis patients receive a blocker of the renin-angiotensin system? / Sinha, Arjun; Agarwal, Rajiv.

In: Current Hypertension Reports, Vol. 12, No. 5, 10.2010, p. 356-363.

Research output: Contribution to journalArticle

@article{76cf1aec8a53490f920847c332d23c5c,
title = "Should all hypertensive dialysis patients receive a blocker of the renin-angiotensin system?",
abstract = "Cardiovascular mortality and hypertension remain common in the dialysis population, and two recent meta-analyses have suggested that antihypertensive pharmacotherapy reduces cardiovascular events in dialysis patients. Based on their benefits in other populations, blockers of the renin-angiotensin- aldosterone system (RAAS) are an attractive treatment option. The evidence that RAAS blockers improve surrogate end points is mixed. However, a recent meta-analysis found significant improvement in left ventricular mass with RAAS-blocking drugs in hemodialysis patients. Only a few trials have examined RAAS-blocking drugs and cardiovascular events in dialysis patients, and a recent meta-analysis found no significant benefit in hemodialysis patients. The single trial of peritoneal dialysis patients that reported cardiovascular events found no benefit from RAAS blockers. Fortunately, the risk of hyperkalemia appears low. Based on the available evidence, we cannot categorically recommend that all hypertensive dialysis patients be treated with RAAS blockers. We await the results of adequately powered clinical trials.",
keywords = "ACE inhibitor, ARB, Blood pressure, Cardiovascular events, End-stage renal disease, ESRD, Hemodialysis, Hypertension, Kidney, Mortality, Myocardial infarction, Peritoneal dialysis, RAAS, Renin-angiotensin system, Residual renal function, Stroke, Treatment",
author = "Arjun Sinha and Rajiv Agarwal",
year = "2010",
month = "10",
doi = "10.1007/s11906-010-0137-z",
language = "English (US)",
volume = "12",
pages = "356--363",
journal = "Current Hypertension Reports",
issn = "1522-6417",
publisher = "Current Medicine Group",
number = "5",

}

TY - JOUR

T1 - Should all hypertensive dialysis patients receive a blocker of the renin-angiotensin system?

AU - Sinha, Arjun

AU - Agarwal, Rajiv

PY - 2010/10

Y1 - 2010/10

N2 - Cardiovascular mortality and hypertension remain common in the dialysis population, and two recent meta-analyses have suggested that antihypertensive pharmacotherapy reduces cardiovascular events in dialysis patients. Based on their benefits in other populations, blockers of the renin-angiotensin- aldosterone system (RAAS) are an attractive treatment option. The evidence that RAAS blockers improve surrogate end points is mixed. However, a recent meta-analysis found significant improvement in left ventricular mass with RAAS-blocking drugs in hemodialysis patients. Only a few trials have examined RAAS-blocking drugs and cardiovascular events in dialysis patients, and a recent meta-analysis found no significant benefit in hemodialysis patients. The single trial of peritoneal dialysis patients that reported cardiovascular events found no benefit from RAAS blockers. Fortunately, the risk of hyperkalemia appears low. Based on the available evidence, we cannot categorically recommend that all hypertensive dialysis patients be treated with RAAS blockers. We await the results of adequately powered clinical trials.

AB - Cardiovascular mortality and hypertension remain common in the dialysis population, and two recent meta-analyses have suggested that antihypertensive pharmacotherapy reduces cardiovascular events in dialysis patients. Based on their benefits in other populations, blockers of the renin-angiotensin- aldosterone system (RAAS) are an attractive treatment option. The evidence that RAAS blockers improve surrogate end points is mixed. However, a recent meta-analysis found significant improvement in left ventricular mass with RAAS-blocking drugs in hemodialysis patients. Only a few trials have examined RAAS-blocking drugs and cardiovascular events in dialysis patients, and a recent meta-analysis found no significant benefit in hemodialysis patients. The single trial of peritoneal dialysis patients that reported cardiovascular events found no benefit from RAAS blockers. Fortunately, the risk of hyperkalemia appears low. Based on the available evidence, we cannot categorically recommend that all hypertensive dialysis patients be treated with RAAS blockers. We await the results of adequately powered clinical trials.

KW - ACE inhibitor

KW - ARB

KW - Blood pressure

KW - Cardiovascular events

KW - End-stage renal disease

KW - ESRD

KW - Hemodialysis

KW - Hypertension

KW - Kidney

KW - Mortality

KW - Myocardial infarction

KW - Peritoneal dialysis

KW - RAAS

KW - Renin-angiotensin system

KW - Residual renal function

KW - Stroke

KW - Treatment

UR - http://www.scopus.com/inward/record.url?scp=77958463933&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=77958463933&partnerID=8YFLogxK

U2 - 10.1007/s11906-010-0137-z

DO - 10.1007/s11906-010-0137-z

M3 - Article

C2 - 20821077

AN - SCOPUS:77958463933

VL - 12

SP - 356

EP - 363

JO - Current Hypertension Reports

JF - Current Hypertension Reports

SN - 1522-6417

IS - 5

ER -